Dallas, TX: ReportsandReports announce it will carry Commercial Insight: Cytotoxic Therapies – Drug launches in rare indications to offset the decline in cytotoxic sales Market Research Report in its Store. Browse complete Commercial Insight: Cytotoxic Therapies – Drug launches in rare indications to offset the decline in cytotoxic sales Report Introduction Growth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%. Several blockbuster products are due to undergo patent expiry over the forecast period and the loss of their branded sales will negatively impact on the growth of this market. But the launch of a number of drugs in rare indications will stabilize growth in this market and offset its decline from generic entry. Scope * In-depth analysis of the current and future cytotoxic therapies market across the US, 5EU and Japan, plus a rest of world snapshot * Cytotoxic therapy sales forecasts for brands and generics from 2009 to 2019 * Assessment of the leading cancer brands and drug classes to identify key success factors within this sector * Assess the strategies of the leading companies in the cytotoxics market Highlights Sales of cytotoxic drugs are forecast to decline in the seven major markets from $14 billion in 2009 to $13.9 billion by 2019, at a CAGR of -0.1%. The launch of Dacogen (decitabine; Eisai/Johnson & Johnson) and Vidaza (azacitidine; Celgene) in the 5EU and Japanese markets will slow down the decline in cytotoxic sales over the forecast period. In 2009, Taxotere (docetaxel; Sanofi-Aventis), Eloxatin (oxaliplatin; Sanofi-Aventis) and Alimta (pemetrexed; Eli Lilly) were the top three cytotoxics, with sales over $1 billion. Alimta will remain among the top three brands in 2019, along with Dacogen and Vidaza. The keys events to impact the cytotoxics market in the forecast period involve new drug launches, approvals into new indications and patent expiries. Several products with annual sales of over $1 billion are due to undergo patent expiry over the forecast period, however, new drug launches in rarer indications will compensate for this loss of sales. Reasons to Purchase * Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven major markets over the period 2009 to 2019 * Acquire a detailed account of cytotoxic therapy cancer brand dynamics and the events that drive and limit their market growth * Benchmark the cytotoxic therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot Table Of Contents Overview Catalyst Summary About Datamonitor healthcare About the oncology pharmaceutical analysis team EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor insight into the cytotoxic therapies market Related reports Upcoming related reports Table of Contents 1. MARKET DEFINITION Market definition for this report Cytotoxic therapies by ATC class L1A -Alkylating agents L1B -Antimetabolites L1C -Vinca alkaloids and other plant-derived products L1D -Antineoplastic antibiotics L1X2 -Platinum compounds L1X9 -All other antineoplastics 2. MARKET OVERVIEW Seven major markets Current and future market overview The cytotoxics therapies market is set to experience negative growth to 2019 with a large number of products losing their patents over the next 5 years Patent expiries on the leading cytotoxic brands are set to occur within the next 5 years The US is due to lose nearly half its value by 2019 due to generic erosion of key branded products The antimetabolites are forecast to account for the largest proportion of market share through to 2019 The current leading cytotoxic brands are forecast to lose significant market share by 2019 due to patent expiry The cytotoxics market will experience contract from $14 billion in 2009 to $13.9 billion in 2019 across the seven major pharmaceutical markets Opportunities and threats Opportunity 1: aging population will result in increasing cancer incidence Opportunity 2: oncology therapy sales continue to experience strong growth Opportunity 3: high levels of unmet need Threat 1: Pharma’s transition towards specialist secondary care indications may further increase competition in the oncology market Threat 2: the cost of drug development continues to rise Threat 3: ongoing cost-containment measures US Current and future market assessment The large impact that generic erosion has on sales of branded drugs will cause a decrease in the US cytotoxics market The cytotoxics market will shrink from $7 billion in 2009 to $4.4 billion in 2019 in the US Opportunities and threats Opportunity 1: with a large population and high healthcare expenditure, the US will continue to offer commercial opportunities for drug developers Opportunity 2: healthcare reform will lead to an increase in the number of insured in the US Opportunity 3: closure of the Medicare Part D coverage gap is good news for branded Pharma Threat 1: growing regulatory pressures increase costs and decrease market penetration for Pharma Threat 2: patent expiries and the resulting generic competition will erode branded sales revenues Threat 3: in the long run, US health reform law will intensify cost-containment pressures Japan Current and future market assessment The cytotoxics market in Japan will experience growth of nearly 2% from 2009 to 2019 The cytotoxics market will grow from $2.4 billion in 2009 to $2.8 billion in 2019 in Japan Opportunities and threats Opportunity 1: the aging population represents a large and growing patient base Opportunity 2: generic sales erosion remains low in Japan Opportunity 3: decrease in lag times for launch of new drugs could accelerate new launches Threat 1: government-enforced biennial cuts continue to have a negative effect on market growth Threat 2: healthcare proposal to change current pricing system will be of limited benefit to Japanese Pharma Threat 3: changes to reference pricing will bring down launch prices Five major European markets (5EU) Current and future market assessment The cytotoxics therapies market in the five major EU markets will grow through to 2019 as a result of several key product launches The cytotoxics market will grow from $4.6 billion in 2009 to $6.5 billion in 2019 in the five major European markets Opportunities and threats Opportunity 1: EU Cancer Task Force will improve the availability of information while generating funds for research Opportunity 2: reorganization of the European Medicines Agency (EMA) expected to streamline the EU regulatory process Threat 1: new European drug price reductions are likely to impact the growth of the pharma industry Threat 2: higher generic uptake in less mature EU markets will impact on branded sales revenues Threat 3: the European Commission inquiry into delays in generics market entry will have wide-ranging ramifications for the branded and generics industry Threat 4: Spain’s price cuts and reference groups are driving drug prices down Threat 5: new low reimbursement rate created in France signals the growing pressure for cost-containment Threat 6: NICE will remain a significant hurdle to commercialization of cancer drugs in the UK, despite relaxation of its cost-effectiveness criteria Threat 7: Germany’s new cost-effectiveness analysis system could add to the downward pressure on drug prices Threat 8: additional cuts to the price of oncology drugs are forthcoming in Italy under its pay-for-performance scheme France Current and future market assessment The cytotoxics market will grow from $1.5 billion in 2009 to $1.8 billion in 2019 in France Germany Current and future market assessment The cytotoxics market will grow from $1.1 billion in 2009 to $1.6 billion in 2019 in Germany Italy Current and future market assessment The cytotoxics market will grow from $0.8 billion in 2009 to $1.2 billion in 2019 in Italy Spain Current and future market assessment The cytotoxics market will grow from $0.7 billion in 2009 to $1.1 billion in 2019 in Spain UK Current and future market assessment The cytotoxics market will grow from $5m in 2009 to $1 billion in 2019 in the UK Rest of the world snapshot Current market assessment Rest of the World sales represent 22% of the global cytotoxics market Opportunities and threats Opportunity 1: incidence of cancer is forecast to increase in the BRIC countries Opportunity 2: emerging markets continue to attract despite challenges Threat: cost of new therapies is a barrier to market penetration 3. BRAND DYNAMICS Overview of competitive landscape Alimta and Taxotere will remain among the top 4 leading cytotoxic brands in both 2009 and 2019 Efficacy and toxicity of a drug are the most important drivers of cytotoxic brand choice Trends in marketing strategies Leading cytotoxic brands Taxotere (docetaxel; Sanofi-Aventis) Drug profile Product positioning SWOT analysis Brand forecast to 2019 Taxotere sales are forecast to fall after 2010 to $723m in 2019 Eloxatin (oxaliplatin; Sanofi-Aventis) Drug profile Product positioning SWOT analysis Brand forecast to 2019 Eloxatin sales will continue to fall through to 2019 in response to genericization Alimta (pemetrexed; Eli Lilly) Drug profile Product positioning SWOT analysis Brand forecast to 2019 Alimta’s sales are forecast to exceed $2 billion in 2016 before dropping to $0.7 billion in 2019 Gemzar (gemcitabine; Eli Lilly) Drug profile Product positioning SWOT analysis Brand forecast to 2019 Gemzar sales are forecast to decrease after 2012, losing more than 50% of sales after 2013 4. KEY DEVELOPERS Strategic overview Trends in corporate strategy Approval in multiple tumor types is most likely to result in significant sales A mature and heavily genericized market means Big Pharma’s experience is crucial Currently there are relatively few novel cytotoxics in development Sanofi-Aventis Corporate strategy Oncology cytotoxics portfolio assessment Eli Lilly Corporate strategy Oncology cytotoxics portfolio assessment Portfolio assessment of other leading companies BIBLIOGRAPHY Journal papers Websites Other Datamonitor reports Appendix A – Market Assumptions Forecasting assumptions New product launches Patent expiries Rest of class definition Data definitions, limitations and assumptions Standard units Country group definitions Rest of the World The ‘all other EU countries’ group The ‘Other non-EU countries’ group Forecast methodology Derivation of sales forecasts and pricing trends Exchange rates Report methodology Appendix B About Datamonitor About Datamonitor Healthcare About the Oncology analysis team Disclaimer Browse complete Commercial Insight: Cytotoxic Therapies – Drug launches in rare indications to offset the decline in cytotoxic sales Report Browse all Healthcare Market Research Reports Browse all Datamonitor Market Research Reports Browse all Latest Report Related Reports: Commercial Insight: Cytotoxic Therapies – Market growth will slow due to increasing genericization Pipeline and Commercial Insight: Insomnia – Future of innovative orexin drug class in doubt About Us: Contact:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
Commercial Insight: Cytotoxic Therapies - Drug launches in rare indications to offset the decline in cytotoxic sales now available at ReportsandReport
Posted by
Unknown
on